CD274 and neoplasm: If PS 0-1 and PD-L1 < 50% or unknown: the standard of care is pembrolizumab plus patinum-based chemotherapy regardless of tumor histology, followed by pembrolizumab maintenance therapy (pembrolizumab plus pemetrexed for non-squamous tumors)[8, 34, 38, 57].